Medical Science Systems Announces Publication of Abstracts in Bone and Mineral Society Journal

Medical Science Systems, a biotech company, has made significant advancements in the field of osteoporosis research. The company has announced the publication of three abstracts in the Bone, Volume 23, number 5, (Supplement) of the International Bone and Mineral Society. The abstracts describe a specific IL-1 genotype that is associated with more rapid bone loss after menopause and a proprietary computer program that simulates bone remodeling and osteoporosis with potential applications in drug development, clinical trial design, and patient education.

The research has significant implications for the treatment and prevention of osteoporosis, a disease that affects almost one-third of all women soon after menopause and as many as 90% of all women over the age of 75, leading to 1.5 million fractures each year. According to industry data, an estimated 28 million people suffer from osteoporosis in the U.S. alone, with short-term healthcare costs associated with osteoporotic fractures alone estimated at $14 billion.

Key Takeaways:

• Medical Science Systems has published three abstracts in the Bone, Volume 23, number 5, (Supplement) of the International Bone and Mineral Society, highlighting the company's advancements in osteoporosis research.
• The abstracts describe a specific IL-1 genotype that is associated with more rapid bone loss after menopause and a proprietary computer program that simulates bone remodeling and osteoporosis.
• The research has significant implications for the treatment and prevention of osteoporosis, a disease that affects nearly one-third of all women soon after menopause and as many as 90% of all women over the age of 75.
• The company's genetic susceptibility test for osteoporosis is the first of several products the company is developing aimed at improving women's health and quality of life through early intervention and targeted treatment.
• The test can identify individuals who carry a specific genetic marker associated with accelerated bone loss during and after menopause, allowing for early preventive interventions.
• The company is also developing genetic susceptibility tests for other chronic inflammatory diseases, including coronary artery disease, asthma, and diabetic retinopathy.

Statistics:

• An estimated 28 million people suffer from osteoporosis in the U.S. alone (industry data).
• Osteoporosis affects almost one-third of all women soon after menopause and as many as 90% of all women over the age of 75 (industry data).
• 1.5 million fractures occur each year due to osteoporosis (industry data).
• Short-term healthcare costs associated with osteoporotic fractures alone are estimated at $14 billion (industry data).

Sources:

• "IL-1 Receptor Antagonist Genotype is Associated with Low Bone Mineral Density in Postmenopausal Osteoporosis" by R Eastell, RA Hannon, AIF Blakemore, RGG Russell, GW Duff, Department of Human Metabolism and Clinical Biochemistry and Centre for Integrated Genetics, University of Sheffield, Sheffield, UK. (Abstract W319, p. S375)
• "IL-1 Receptor Antagonist Genotype as a Predictor of Bone Loss in Postmenopausal Women" by R Eastell, RA Hannon, RGG Russell, GW Duff, Department of Human Metabolism and Clinical Biochemistry and Centre for Integrated Genetics, University of Sheffield, Sheffield, UK, and S van Dijk, Medical Science Systems, Inc. (Abstract W322, p. S375)
• "IL-1 Receptor Antagonist as a Potential New Therapeutic Agent for Osteoporosis: A Computer Simulation Model of Bone Remodeling and Osteoporosis", by LT Herren, S van Dijk, HY Wang, K. Kornman, Medical Science Systems, Inc. (Abstract SA399, p. S620)
• Patent number 5,698,399, awarded to Medical Science Systems, Inc. for patent claims related to the IL-1 association with osteoporosis.
• Medical Science Systems, Inc. Form SB2 filed October 8, 1997, as amended (Commission file #333-37441), and the Company's 10K-SB dated December 31, 1997.